Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome

Jiu Yao Wang, Tsu Fuh Yeh, Yu Chih Lin, Kazuo Miyamura, Uffe Holmskov, Kenneth B.M. Reid

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background - Early postnatal use of dexamethasone in infants with respiratory distress syndrome (RDS) has been shown effectively to improve pulmonary status and to allow early weaning off mechanical ventilation. However, the mechanisms to explain the beneficial effects of dexamethasone in ventilatory dependent preterm infants remain unclear. Methods - A double blind, placebo controlled study was performed to determine the change in pulmonary ventilation of premature infants with RDS as a result of dexamethasone treatment, and to evaluate the effect of dexamethasone on the levels of surfactant-associated proteins A (SP-A) and D (SP-D) in the tracheal fluid from 34 premature infants with RDS and 29 control subjects. Results - Dexamethasone treatment decreased fractional inspired oxygen concentration (FIO2), arterial carbon dioxide tension (PCO2), mean airway pressure (MAP), and facilitated successful weaning from mechanical ventilation. SP-A concentrations in the tracheal aspirates were increased at days 7 and 14, and SP-D concentrations were increased during the period from days 3 to 14 in the dexamethasone treated group compared with the control group. However, albumin levels in the tracheal aspirate samples were decreased after dexamethasone treatment over the period from days 3 to 14. There was an inverse correlation between PCO2 values and SP-A concentrations. Conclusions - These result suggest that early use of dexamethasone can improve pulmonary status and also increase SP-A and SP-D levels in the tracheal fluid in premature infants with RDS.

Original languageEnglish
Pages (from-to)907-913
Number of pages7
JournalThorax
Volume51
Issue number9
DOIs
Publication statusPublished - Jan 1 1996
Externally publishedYes

Fingerprint

Pulmonary Surfactant-Associated Proteins
Newborn Respiratory Distress Syndrome
Dexamethasone
Staphylococcal Protein A
Pulmonary Surfactant-Associated Protein D
Premature Infants
Surface-Active Agents
Therapeutics
Artificial Respiration
Pulmonary Ventilation
Lung
Weaning
Double-Blind Method
Carbon Dioxide
Albumins
Placebos
Oxygen
Pressure

Keywords

  • Bronchopulmonary dysplasia
  • Dexamethasone
  • Respiratory distress syndrome (RDS)
  • Surfactant proteins A and D (SP-A and SP-D)
  • Tracheal aspirates

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. / Wang, Jiu Yao; Yeh, Tsu Fuh; Lin, Yu Chih; Miyamura, Kazuo; Holmskov, Uffe; Reid, Kenneth B.M.

In: Thorax, Vol. 51, No. 9, 01.01.1996, p. 907-913.

Research output: Contribution to journalArticle

Wang, Jiu Yao ; Yeh, Tsu Fuh ; Lin, Yu Chih ; Miyamura, Kazuo ; Holmskov, Uffe ; Reid, Kenneth B.M. / Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. In: Thorax. 1996 ; Vol. 51, No. 9. pp. 907-913.
@article{085c495bd2b8416fa2fcafcc17ee5ed2,
title = "Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome",
abstract = "Background - Early postnatal use of dexamethasone in infants with respiratory distress syndrome (RDS) has been shown effectively to improve pulmonary status and to allow early weaning off mechanical ventilation. However, the mechanisms to explain the beneficial effects of dexamethasone in ventilatory dependent preterm infants remain unclear. Methods - A double blind, placebo controlled study was performed to determine the change in pulmonary ventilation of premature infants with RDS as a result of dexamethasone treatment, and to evaluate the effect of dexamethasone on the levels of surfactant-associated proteins A (SP-A) and D (SP-D) in the tracheal fluid from 34 premature infants with RDS and 29 control subjects. Results - Dexamethasone treatment decreased fractional inspired oxygen concentration (FIO2), arterial carbon dioxide tension (PCO2), mean airway pressure (MAP), and facilitated successful weaning from mechanical ventilation. SP-A concentrations in the tracheal aspirates were increased at days 7 and 14, and SP-D concentrations were increased during the period from days 3 to 14 in the dexamethasone treated group compared with the control group. However, albumin levels in the tracheal aspirate samples were decreased after dexamethasone treatment over the period from days 3 to 14. There was an inverse correlation between PCO2 values and SP-A concentrations. Conclusions - These result suggest that early use of dexamethasone can improve pulmonary status and also increase SP-A and SP-D levels in the tracheal fluid in premature infants with RDS.",
keywords = "Bronchopulmonary dysplasia, Dexamethasone, Respiratory distress syndrome (RDS), Surfactant proteins A and D (SP-A and SP-D), Tracheal aspirates",
author = "Wang, {Jiu Yao} and Yeh, {Tsu Fuh} and Lin, {Yu Chih} and Kazuo Miyamura and Uffe Holmskov and Reid, {Kenneth B.M.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1136/thx.51.9.907",
language = "English",
volume = "51",
pages = "907--913",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome

AU - Wang, Jiu Yao

AU - Yeh, Tsu Fuh

AU - Lin, Yu Chih

AU - Miyamura, Kazuo

AU - Holmskov, Uffe

AU - Reid, Kenneth B.M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Background - Early postnatal use of dexamethasone in infants with respiratory distress syndrome (RDS) has been shown effectively to improve pulmonary status and to allow early weaning off mechanical ventilation. However, the mechanisms to explain the beneficial effects of dexamethasone in ventilatory dependent preterm infants remain unclear. Methods - A double blind, placebo controlled study was performed to determine the change in pulmonary ventilation of premature infants with RDS as a result of dexamethasone treatment, and to evaluate the effect of dexamethasone on the levels of surfactant-associated proteins A (SP-A) and D (SP-D) in the tracheal fluid from 34 premature infants with RDS and 29 control subjects. Results - Dexamethasone treatment decreased fractional inspired oxygen concentration (FIO2), arterial carbon dioxide tension (PCO2), mean airway pressure (MAP), and facilitated successful weaning from mechanical ventilation. SP-A concentrations in the tracheal aspirates were increased at days 7 and 14, and SP-D concentrations were increased during the period from days 3 to 14 in the dexamethasone treated group compared with the control group. However, albumin levels in the tracheal aspirate samples were decreased after dexamethasone treatment over the period from days 3 to 14. There was an inverse correlation between PCO2 values and SP-A concentrations. Conclusions - These result suggest that early use of dexamethasone can improve pulmonary status and also increase SP-A and SP-D levels in the tracheal fluid in premature infants with RDS.

AB - Background - Early postnatal use of dexamethasone in infants with respiratory distress syndrome (RDS) has been shown effectively to improve pulmonary status and to allow early weaning off mechanical ventilation. However, the mechanisms to explain the beneficial effects of dexamethasone in ventilatory dependent preterm infants remain unclear. Methods - A double blind, placebo controlled study was performed to determine the change in pulmonary ventilation of premature infants with RDS as a result of dexamethasone treatment, and to evaluate the effect of dexamethasone on the levels of surfactant-associated proteins A (SP-A) and D (SP-D) in the tracheal fluid from 34 premature infants with RDS and 29 control subjects. Results - Dexamethasone treatment decreased fractional inspired oxygen concentration (FIO2), arterial carbon dioxide tension (PCO2), mean airway pressure (MAP), and facilitated successful weaning from mechanical ventilation. SP-A concentrations in the tracheal aspirates were increased at days 7 and 14, and SP-D concentrations were increased during the period from days 3 to 14 in the dexamethasone treated group compared with the control group. However, albumin levels in the tracheal aspirate samples were decreased after dexamethasone treatment over the period from days 3 to 14. There was an inverse correlation between PCO2 values and SP-A concentrations. Conclusions - These result suggest that early use of dexamethasone can improve pulmonary status and also increase SP-A and SP-D levels in the tracheal fluid in premature infants with RDS.

KW - Bronchopulmonary dysplasia

KW - Dexamethasone

KW - Respiratory distress syndrome (RDS)

KW - Surfactant proteins A and D (SP-A and SP-D)

KW - Tracheal aspirates

UR - http://www.scopus.com/inward/record.url?scp=0029739010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029739010&partnerID=8YFLogxK

U2 - 10.1136/thx.51.9.907

DO - 10.1136/thx.51.9.907

M3 - Article

C2 - 8984701

AN - SCOPUS:0029739010

VL - 51

SP - 907

EP - 913

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 9

ER -